




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Pulmonary Hypertension and Venous Thromboembolism</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=9cb8eff7-d78e-4dfc-a992-2905830cc91f</link>
        <description>Clinical Topic Feed: Pulmonary Hypertension and Venous Thromboembolism</description>
        <language>en</language>

        

                <item>
                    <title>ACC Featured Jobs For September 2026</title>
<link>/Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs</link>                    <description>Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!</description>
                    <pubdate>1788305160000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | Persistent Excess CV Mortality in Black Americans; TAVR at 10 Years; More</title>
<link>/Latest-in-Cardiology/Articles/2026/09/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1788264600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PADN-HF-PH: Pulmonary-Artery Denervation For Pulmonary Hypertension Associated With Left Heart Disease and HF</title>
<link>/Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-324am-padn-esc-2026</link>                    <description>Pulmonary-artery denervation, in addition to guideline-directed medical therapy, resulted in fewer events of clinical worsening than medical therapy alone in patients with pulmonary hypertension associated with left heart disease and heart failure (HF), based on findings from the PADN-HF-PH trial presented at ESC Congress 2026 and simultaneously published in NEJM.</description>
                    <pubdate>1788082020000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC Journals&#226;€™ Abstracts Explore Novel Therapies, Role of Precision Medicine, and More</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-journals-esc-2026</link>                    <description>Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care.</description>
                    <pubdate>1788002340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Clinical Practice Algorithm For the Follow-Up of Unrepaired and Repaired Ventricular Septal Defects</title>
<link>/Latest-in-Cardiology/Articles/2023/05/30/10/47/Clinical-Practice-Algorithm-For-the-Follow-Up-of-Unrepaired-and-Repaired-Ventricular-Septal-Defects</link>                    <description>Ventricular septal defects (VSDs) are the most common form of congenital heart disease (CHD) diagnosed in childhood. There is a wide variation in clinical practice for the management of common types of VSDs.</description>
                    <pubdate>1787745480000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Clinical Practice Algorithm For the Follow-Up of Unrepaired and Repaired Patent Ductus Arteriosus</title>
<link>/Latest-in-Cardiology/Articles/2022/10/31/13/02/Clinical-Practice-Algorithm-For-the-Follow-Up-of-Unrepaired-and-Repaired-PDA</link>                    <description>Isolated patent ductus arteriosus (PDA) is a relatively common defect, accounting for 5-10% of congenital heart defects (excluding premature infants).1 Given the increased use of echocardiography, incidental detection of asymptomatic silent PDAs is on the rise.</description>
                    <pubdate>1787745300000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Endometriosis Tied to Higher Long-Term VTE Risk</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/18/18/12/Endometriosis-Tied-to-Higher-Long-Term-VTE-Risk</link>                    <description>Endometriosis was associated with an approximately 50% greater long-term risk of venous thromboembolism (VTE), including higher risks of deep venous thrombosis (DVT) and pulmonary embolism (PE), compared with no endometriosis, according to research published Aug. 8 in the EHJ.</description>
                    <pubdate>1787238660000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ADVANCE OUTCOMES: Ralinepag Reduces Clinical Worsening For PAH</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/ADVANCE-OUTCOMES</link>                    <description>Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.</description>
                    <pubdate>1785862800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: ACC Updated Expert Consensus Decision Pathway on HFpEF</title>
<link>/Latest-in-Cardiology/Articles/2026/07/29/13/18/eagles-eye-view-29jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis.</description>
                    <pubdate>1785331140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>API-CAT Analysis: Recurrent VTE Uncommon, Associated With Poor Short-Term Survival</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/20/14/38/API-CAT-Analysis</link>                    <description>Recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival among patients with cancer-associated thrombosis on extended apixaban therapy after at least six months of anticoagulation treatment, according to a post-hoc analysis of the API-CAT trial published July 13 in Circulation.</description>
                    <pubdate>1784571060000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>